Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

Ascentage Pharma China Maryland

View original content:https://www.prnewswire.co.uk/news-releases/global-registrational-phase-iii-study-of-olverembatinib-for-the-treatment-of-patients-with-sdh-deficient-gist-approved-by-the-china-cde-302168892.html